Boehringer Ingelheim Expanded Detect the SOS Mission
The pharmaceutical company launched a global initiative to increase urine albumin-to-creatinine ratio testing for heart risk.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Would you ask your doctor for specific screening tests to detect hidden heart or kidney risks?
Boehringer Ingelheim has expanded its Detect the SOS mission globally to promote the use of urine albumin-to-creatinine ratio (uACR) testing. The initiative aims to integrate these screenings into routine primary-care health checks to identify early signs of vascular damage.
Why it matters
More than half of individuals at risk for chronic kidney disease currently miss out on crucial uACR testing, which identifies early indicators of vascular system damage. Detecting these markers early could help mitigate the severe risks posed by cardiovascular disease, which causes over 20 million deaths annually.
A uACR level of 30 mg/g is associated with a 90% higher risk of heart failure, a 70% increased risk of cardiovascular death, and a 60% higher risk of heart attack and stroke. Testing implementation rates remain low, with 21% in the U.S. and under 1% in Germany.
The players
Boehringer Ingelheim
A global research-driven pharmaceutical company that focuses on human and animal health.
World Heart Federation
An international organization based in Switzerland that unites the heart health community.
European Kidney Patients Federation
A non-profit organization representing the interests of kidney patients across Europe.
Mended Hearts Europe
A patient advocacy group providing support to those affected by cardiovascular disease.
The details
Boehringer Ingelheim is partnering with the European Kidney Patients Federation, Mended Hearts Europe, and the World Heart Federation to advocate for standardized screening practices. The program focuses on influencing national health plans to ensure that patients with type 2 diabetes and hypertension receive regular testing.
Timeline
September 28, 2026 marks the commencement of EU Screening Week.
September 29, 2026 coincides with the World Heart Day campaign.
The Big Picture
This initiative follows the preventative screening priorities established by the World Heart Federation to address global cardiovascular outcomes. By standardizing diagnostic testing, the mission aims to shift primary care from reactive treatment to proactive disease management.
Patients with hypertension or type 2 diabetes should consult their primary care providers about including uACR testing in their next check-up. Early detection of albuminuria can lead to earlier intervention and reduced long-term risk of cardiovascular events.
The takeaway
Proactive testing for albuminuria provides a critical window to identify heart risks before they escalate into life-threatening emergencies. Patients are encouraged to prioritize routine kidney function markers as part of their comprehensive cardiovascular health plan.
Further reading
Learn more about the latest diagnostic approaches in Heart Disease.
Live Poll
Would you ask your doctor for specific screening tests to detect hidden heart or kidney risks?
